


# Exemestane



## CAS

107868-30-4

## Status

Commercial

[Inquiry](#)

Exemestane has a steroid skeleton and can inhibit the aromatase inhibitors. This prevents the synthesis of estrogens from androgens in non-ovarian tissues. This effect makes hormone-dependent (estrogen receptor-positive) breast cancer treatable. At present, it is only used if tamoxifen is insufficient. In sports, it is abused by the almost dose-independent achievable dominance of male hormones. Exemestane has no gestagenic or estrogenic effects.

## Description

**Formula**  $C_{20}H_{24}O_2$

**Molecular weight** 296.40 g/mol

**Molecular size** small

**Controlled Substance** no

**Precursor** no

**Indications** Endocrine therapy

## Your Contact



**Marius Hang**  
*International Division*  
*Director API Export*

Midas Pharma GmbH  
Rheinstr. 49  
55218 Ingelheim  
Germany  
[Send E-Mail](#)

### Disclaimer

*The information contained herein is the proprietary information of Midas Pharma GmbH and its affiliates. This information is provided to you solely for your evaluation, to determine your interest in a potential business relationship with Midas Pharma GmbH and/or its affiliates. Midas Pharma GmbH excludes any express or implied representations, guarantees or warranties of whatsoever nature, including but not limited to the warranties for the completeness or accuracy of the information provided herein.*

*No information provided herein – including any reference to any product or service – constitutes an offer for sale, or shall be construed as representing an offer for sale. In particular, nothing herein should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.*